Vanguard Group Inc Clearside Biomedical, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,806,607 shares of CLSD stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,806,607
Previous 2,806,607
-0.0%
Holding current value
$1.09 Million
Previous $2.81 Million
7.98%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CLSD
# of Institutions
51Shares Held
11.4MCall Options Held
5.9KPut Options Held
86.6K-
Act Capital Management, LLC Wayne, PA2.2MShares$857,0173.43% of portfolio
-
Carmignac Gestion Paris, I01.51MShares$588,2530.02% of portfolio
-
Black Rock Inc. New York, NY798KShares$311,2730.0% of portfolio
-
Geode Capital Management, LLC Boston, MA792KShares$308,9760.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny555KShares$216,2590.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $23.5M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...